Fortis Healthcare shares dipped 1.19% to ₹868.50 on the BSE, falling ₹10.50 from the previous close. The move followed the company’s announcement of a 29‑year Healthcare Services Agreement with the Seth Sunder Lal Jain Charitable Eye Hospital in Ashok Vihar.
Dr Ashutosh Raghuvanshi, MD and CEO, said the pact “marks an important collaboration aimed at enhancing access to quality healthcare in North‑West Delhi.” Under the deal, Fortis will have exclusive rights to provide inpatient services and specialist equipment—including a cath lab, LINAC, PET‑CT and surgical robot—over the term, while the hospital itself will be owned and managed by the SLJ Society.
Fortis will provide a phased loan to the SLJ Society over the next 3–4 years, tied to construction progress, and will receive a service fee for its operational role. No specific fee amount was disclosed, but the long‑term contract could generate a steady revenue stream once the 400‑plus bed facility opens.
The healthcare sector in Delhi is crowded, with several private players vying for market share in oncology and cardiology. Analysts note that a 29‑year agreement is rare and could give Fortis a competitive edge, yet the delayed operational window and pending approvals temper enthusiasm.
Investors are watching the upcoming regulatory review closely. Fortis has not issued new guidance, but the company will likely discuss the pact’s financial impact in its next earnings release, scheduled for the end of the next fiscal quarter.